Abstract: The invention provides methods and compositions for treating erectile dysfunction. The methods include the step of placing within the fossa navicularis of the patient an effective erection-inducing amount of a vasoactive prostaglandin composition of a semi-solid consistency. The composition comprises a vasoactive prostaglandin, a penetration enhancer, a shear-thinning polysaccharide, a lipophilic compound, and an acidic buffer system. The penetration enhancer is an alkyl-2-(N-substituted amino)-alkanoate ester, a (N-substituted amino)-alkanol alkanoate, or a mixture of these enhancers. The lipophilic compound may be an aliphatic C1 to C8 alcohol, aliphatic C2 to C30 ester, an aliphatic C8 to C30 ester, or a mixture of these. The composition includes a buffer system providing a buffered pH value for said composition in the range of about 3 to about 7.4.

Abstract: Compositions and methods for the treatment of vasospasm are provided comprising applying an amount of a semi-solid vasoactive prostaglandin composition to the affected tissue. Also provided are methods of improving microcirculation in a replanted body part.

Abstract: Compounds of prostaglandin E group (PGE compounds) are stabilized as non-aqueous compositions that include the compound together with a bulking agent that can be a non-aqueous liquid or a solid in a sheet, film or powder form. The composition can optionally include a skin penetration enhancer. A non-aqueous, solid dosage form comprises a PGE compound substantially uniformly distributed in a carrier sheet or film.

Abstract: The invention provides compositions and methods suitable for ameliorating female sexual dysfunction, and in particular, female sexual arousal disorder. In preferred embodiments, the invention provides a semisolid composition suitable for topical application comprising: an effective amount of a vasoactive prostaglandin, a penetration enhancer, a polymer thickener, a lipophilic component, and an acidic buffer system. In other embodiments, the invention provides a method of treating female sexual arousal disorder by applying an effective dose of a topical semisolid prostaglandin composition to the anterior wall of the vagina.

Abstract: The present invention provides compositions and methods of use for treatment of erectile dysfunction associated with neuropathy related to diabetes, prostatectomy, cysto-prostatectomy, radical cystectomy, abdominoperineal resection of the rectum, cryoablation or radiation therapy.

Abstract: The present invention provides compositions and methods for promoting the recovery of vascular function in erectile dysfunction associated with vasculopathy by administering a composition comprising a vasoactive prostaglandin and a biocompatible polymer. In preferred embodiments, the prostaglandin composition is a topical composition comprising prostaglandin E1, a biocompatible polymer and a penetration enhancer and the topical composition is applied to the meatus at the tip of the penis. In another embodiment, the invention provides a method for increasing microvascular outgrowth at a targeted arterial segment comprising administering a prostaglandin E1 composition to produce an extracellular prostaglandin E1 concentration of about 1 micromolar to about 10 micromolar adjacent to the targeted arterial segment for about four days.

Abstract: Compositions and methods for the treatment of premature ejaculation are provided wherein a composition comprising a topical anesthetic, a shear-thinning polymeric thickener, a lipophilic component that is selected from the group consisting of an aliphatic C1 to C8 alcohol, an aliphatic C8 to C30 ester, a liquid polyol and a mixture thereof, water and a buffer system that provides a buffered pH value for the composition in the range of about 3 to about 7.4 is administered to the penile meatus.

Abstract: The invention provides compositions and methods suitable for ameliorating female sexual dysfunction, and in particular, female sexual arousal disorder. In one embodiment, the invention provides a semisolid composition suitable for topical application comprising: an effective amount of a vasoactive prostaglandin, a polysaccharide thickener, a lipophilic component, and an acidic buffer system.

Abstract: The invention provides methods for the treatment of erectile dysfunction in a patient suffering from a co-morbid condition comprising placing in the fossa navicularis of the patient an erection-inducing amount of a semi-solid vasoactive prostaglandin composition.

Abstract: Methods for the treatment of erectile dysfunction are provided comprising placing in the fossa navicularis an amount of a semi-solid vasoactive prostaglandin composition sufficient to increase blood flow in the glans penis and resulting in increased tumescence of the penis. In preferred embodiments, the method further comprises providing erotic stimuli. Another embodiment, the invention provides a method for increasing the tumescence of the glans penis. In another aspect, the invention provides compositions and articles of manufacture for the practice of the methods of the invention.

Abstract: The invention provides methods and compositions for treating erectile dysfunction. The methods include the step of placing within the fossa navicularis of the patient an effective erection-inducing amount of a vasoactive prostaglandin composition of a semi-solid consistency. The composition comprises a vasoactive prostaglandin, a penetration enhancer, a shear-thinning polysaccharide, a lipophilic compound, and an acidic buffer system. The penetration enhancer is an alkyl-2-(N-substituted amino)-alkanoate ester, a (N-substituted amino)-alkanol alkanoate, or a mixture of these enhancers. The lipophilic compound may be an aliphatic C1 to C8 alcohol, aliphatic C2 to C30 ester, an aliphatic C8 to C30 ester, or a mixture of these. The composition includes a buffer system providing a buffered pH value for said composition in the range of about 3 to about 7.4.

Abstract: An electrical stimulation apparatus and method for providing electrical stimulation to tissue. The electrical stimulation apparatus includes a base unit and an electrode module. The base unit is configured to be hand portable and contains a first electrical circuit and a first battery for supplying electrical energy to the first electrical circuit. A second electrical circuit and a second battery provide a time/date function. The base unit supports an LCD to provide a visual indication of the various functions of the electrical stimulation apparatus. The electrode module is programmable to enable the prescribing physician to set the treatment protocol for the electrical stimulation apparatus. The present apparatus is particularly well suited for the treatment of herpes simplex and herpes zoster.

Abstract: The invention provides compositions and methods suitable for ameliorating female sexual dysfunction, and in particular, female sexual arousal disorder. In one embodiment, the invention provides a semisolid composition suitable for topical application comprising: an effective amount of a vasoactive prostaglandin, a polysaccharide thickener, a lipophilic component, and an acidic buffer system.

Abstract: The invention provides a composition suitable for topical application comprising: an effective amount of a prostaglandin, a polymer thickener, a lipophilic component, and a buffer system. In another embodiment, the invention provides a composition suitable for topical application comprising: an effective amount of a vasoactive agent, a polymer thickener, a lipophilic component, and a buffer system. The invention also provides methods of ameliorating female sexual dysfunction. Also provided are methods of increasing female sexual arousal and methods of enhancing female sexual response.

Abstract: A topical composition of a semi-solid consistency suitable is provided for transdermal application of prostaglandin E1. The composition comprises prostaglandin E1, a penetration enhancer, a polysaccharide gum, a lipophilic compound, and an acidic buffer system. The penetration enhancer is an acid addition salt of an alkyl-2-(substituted amino)-alkanoate ester, of a (substituted amino)-alkanol alkanoate, or of a mixture thereof. The lipophilic compound may be an aliphatic C1 to C8 alcohol, an aliphatic C8 to C30 ester, or a mixture of these. The composition includes a buffer system capable of providing a buffered pH value for said composition in the range of about 3 to about 7.4.

Abstract: The invention provides methods of treating erectile dysfunction comprising the step of placing within the fossa navicularis of the patient an effective erection-inducing amount of a prostaglandin E1 composition of a semi-solid consistency, as well as suitable applicators. The composition comprises prostaglandin E1, a penetration enhancer, a polysaccharide gum, a lipophilic compound, and an acidic buffer system. The penetration enhancer is an alkyl-2-(N,N-disubstituted amino)-alkanoate ester, an (N,N-disubstituted amino)-alkanol alkanoate, or a mixture of these. The lipophilic compound may be an aliphatic C1 to C8 alcohol, aliphatic C2 to C30 ester, an aliphatic C8 to C30 ester, or a mixture of these. The composition includes a buffer system capable of providing a buffered pH value for said composition in the range of about 3 to about 7.4.

Abstract: The invention provides methods of treating erectile dysfunction comprising the step of placing within the fossa navicularis of the patient an effective erection-inducing amount of a prostaglandin E1 composition of a semi-solid consistency. The composition comprises prostaglandin E1, a penetration enhancer, a polysaccharide gum, a lipophilic compound, and an acidic buffer system. The penetration enhancer is an alkyl-2-(N,N-disubstituted amino)-alkanoate ester, an (N,N-disubstituted amino)-alkanol alkanoate, or a mixture of these. The lipophilic compound may be an aliphatic C1 to C8 alcohol, an aliphatic C8 to C30 ester, or a mixture of these. The composition includes a buffer system capable of providing a buffered pH value for said composition in the range of about 3 to about 7.4.

Abstract: A disposable applicator for dispensing a desired quantity of a substantially non-runny medicant medicament, including a housing, a plunger and a replaceable cap. The housing is generally tubular having opposing proximal and distal ends and a tapered inner surface extending therebetween. The distal end terminates in a dispensing nozzle that defines a dispensing passageway in substantial coaxial alignment with the housing, while the inner surface has an alignment device. The plunger has a peripheral edge and is configured for axial movement within the housing, where the peripheral edge is aligned by the alignment device and slidingly guided by the inner surface, supporting the plunger therein. The plunger is configured for slidable advancement toward the dispensing opening by exertion of force by a user, so as to urge the medicament through the passageway.

Abstract: Dodecyl 2-(N,N dimethylamino)-propionate (DDAIP) is prepared by transesterification of ethyl 2-(N,N-dimethylamino) propionate. Crystalline acid addition salts of DDAIP are prepared by cooled mixing of DDAIP with one of a select group of acids in the presence of a water immiscible solvent such as hexane. The resulting DDAIP salts are crystalline, and exhibit a pattern of defined detection peaks upon analysis by powder x-ray diffraction.

Abstract: An aqueous pharmaceutical composition of a semi-solid consistency is provided for topical application of non-steroidal anti-inflammatory (NSAI) drugs. The composition comprises one or more NSAI drugs, a non-basic polymeric skin penetration enhancer and a lipophilic solvent. The polymeric skin penetration enhancer is present in an amount sufficient to enhance skin penetration of the NSAI drug. The lipophilic solvent is a mixture of an aliphatic C.sub.2 to C.sub.8 alcohol and an aliphatic C.sub.8 to C.sub.30 ester.